Kellee Miller, United States of America
Jaeb Center for Health Research WISDMPresenter of 1 Presentation
BENEFIT OF CONTINUOUS GLUCOSE MONITORING (CGM) IN REDUCING HYPOGLYCEMIA IS SUSTAINED THROUGH 12 MONTHS OF USE AMONG OLDER ADULTS WITH TYPE 1 DIABETES (T1D)
Abstract
Background and Aims
The Wireless Innovation for Seniors with Diabetes Mellitus (WISDM) randomized clinical trial demonstrated reductions in hypoglycemia with CGM compared with blood glucose monitoring over 6 months among older adults with T1D. To determine if this improvement could be sustained over a longer period with less intensive follow-up, participants in the CGM group continued CGM through 12 months.
Methods
Of the adults ≥60 years with T1D (in the RCT CGM group, 100 of 103 (97%) continued on CGM and completed 12 months of follow-up (58% female, median age 68 years, 92% non-Hispanic white, and 58% used insulin pumps). CGM-measured outcomes were calculated at baseline (masked CGM) and 4 weeks prior to each visit over 12 months.
Results
Median percent time <70 mg/dL was reduced from 5.0% at baseline to 2.8% at 12 months (p<0.001). This improvement was evident in the first month and sustained through 12 months (Figure). Similar improvements were observed for time <54 mg/dL (median 1.9% versus 0.4%; p<0.001). In addition, participants spent more time in range 70-180 mg/dL (mean 56% versus. 64%; p<0.001), spent less time in hyperglycemia >180 mg/dL (mean 37% vs. 33%; p<0.001), and had better HbA1c (mean 7.6% versus 7.4%; p=0.01) at 12 months compared with baseline. CGM use remained high with 85% using the sensor ≥6 days per week at both 6 and 12 months.
Conclusions
These results demonstrate CGM may be used effectively in older adults with T1D and provide evidence for further integrating this technology into clinical practice.